Abbott to launch new production of hospital drugs in Russia this year

19 February 2019

US drugmaker Abbott (NYSE: ABT) says it will expand its Russian production in the Vladimir region this year by the commissioning of two new lines for the production of hospital drugs and the xylene nasal drops, according to an official spokesman of the Vladimir authorities, reports The Pharma Letter’s local correspondent.

Financial and technical details of the project are not disclosed, however the project will be implemented by Abbott through its local Veropharm subsidiary.

Currently, the Vladimir plant is one of the three manufacturing facilities in Russia that is operated by Veropharm and which is part of Abbott group.

Currently the enterprise mainly specializes on the production of injectable liquid and lyophilic forms of drugs for the treatment of cancer and has a status of one of Russia’s largest producers of anticancer drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK